Giving access to affordable high-quality healthcare is one of the toughest and major challenges. Janssen works on initiatives to create a world where people, regardless of their economic and social circumstances, have access to the treatments they need.
The creation of Janssen Global Public Health (GPH) in 2013 was a new step in the company's ambitions to solve the global public health challenges. Janssen GHP is responsible for a growing portfolio of pharmaceutical products and services for sick people with a large impact on public health.
As a leading healthcare organization Janssen aims to offer pioneering medical innovations to patients around the world. The company is keen to take healthcare innovations and solutions to more people and more places in the world. Regardless of where these people live and their ability to pay for it.
Janssen GPH will be responsible for the full clinical development of products and services and for maximizing access to medicines and care for patients worldwide. In doing so, the organization focuses on huge medical needs, in particular HIV, tuberculosis, hepatitis C and worm diseases.
Janssen GPH will also be the central point of contact for the cooperation with the parties involved globally in terms of public health, such as governments, non-governmental organizations and funding organizations.
Janssen is also dedicated to helping HIV/AIDS patients by offering a more effective and sustainable access to HIV medication. We believe that effective HIV drug access has two important components: ensuring quality and affordable medicines are available sustainably and that they are used in the most appropriate way for patients.
In 2006 Janssen introduced the Global Access and Partnerships Program (GAPP), a worldwide programme to fulfil the responsibility to people living with HIV/AIDS in resource-limited countries.
GAPP's HIV drug access efforts are focused on countries with the highest rates of HIV infection and economic vulnerability. Such as sub-Saharan Africa (SSA), least developed countries, and lower middle-income countries. A variety of factors influence our approach to HIV drug access - including the approved indications of each of our medicines and how they are used in clinical practice.
The Immersion programme was also set up to ambitiously tackle global health issues. Experiments, taking risks, innovative ideas, and immersion in other cultures and ways of thinking are central in the approach based on the ideas and passions of Johnson & Johnson employees worldwide.
Immersion drives ideas through the organization, puts together small teams and launched projects with limited budget and resources worldwide. Every project can be compared to a starting company looking for its own path to follow, exploring, developing ideas and focused on results. The project teams are supported throughout the process by means of coaching and workshops to develop projects which can promote access to healthcare, provide directly measurable results and lead to new forms of cooperation.
Together with all kinds of partners, including governments and (supra)national organizations, Immersion teams are looking for solutions for local healthcare problems. A few projects have already been launched, including on sustainable ageing in Poland, the fight against tuberculosis worldwide and on a European scale, the introduction of 'social impact bonds', a new market model to fight hepatitis C in Romania and a fully transparent digital data platform.
Immersion is launched by the Janssen Global Commercial Strategy Operations (GCSO) organization, and more specifically the recently founded Global Public Health group. All employees can contribute and develop ideas or join an existing project.
Besides, Janssen was the first pharmaceutical company to donate Janssen medicines in the context of a treatment programme for children and adolescents in Sub Saharan Africa. The treatment of HIV in children in that region is seriously neglected and is usually, if present at all, restricted to first-line care. The healthcare programme demonstrates the years of efforts made by Janssen to help people with HIV. The efforts are aimed at countries with the highest HIV infection levels and the highest economic vulnerability.
The programme is intended as a first step in a broader collaboration relation in Sub-Saharan Africa to give patients long-term access to HIV medicines. With it Janssen intends to raise the awareness and stimulate further actions, such as giving training in second and third line pediatric HIV treatment in Sub-Saharan Africa. To this end Janssen collaborates with the Elizabeth Glaser Pediatric AIDS Foundation, the Partnership for Supply Chain Management (PFSCM) and MAP International.